Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis
Latest Information Update: 13 Mar 2024
At a glance
- Drugs IRL 201805 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Revolo Biotherapeutics
- 22 Dec 2022 Status changed from planning to recruiting.
- 04 Feb 2022 According to Revolo Biotherapeutics media release, the company has received approval from the The Medicines and Healthcare Products Regulatory Agency (MHRA) to commence this trial.
- 05 Mar 2021 According to an Immune Regulation media release, this trial is planned in second half of 2021